Increasing numbers of patients internationally are taking dual antiplatelet therapy (DAPT). Both continuing and stopping this treatment may be risky for the patient. It is vital to consider the competing thrombotic and bleeding risks in the perioperative period. It is incumbent upon anaesthetists to maintain their knowledge base in this rapidly developing area. This article provides information to support practice as.
Elbarbary, D. H. (2019). Antiplatelet therapy and the anaesthetist. The Egyptian Journal of Cardiothoracic Anesthesia, 13(1), -. doi: 10.4103/ejca.ejca_18_18
MLA
Dina H. Elbarbary. "Antiplatelet therapy and the anaesthetist", The Egyptian Journal of Cardiothoracic Anesthesia, 13, 1, 2019, -. doi: 10.4103/ejca.ejca_18_18
HARVARD
Elbarbary, D. H. (2019). 'Antiplatelet therapy and the anaesthetist', The Egyptian Journal of Cardiothoracic Anesthesia, 13(1), pp. -. doi: 10.4103/ejca.ejca_18_18
VANCOUVER
Elbarbary, D. H. Antiplatelet therapy and the anaesthetist. The Egyptian Journal of Cardiothoracic Anesthesia, 2019; 13(1): -. doi: 10.4103/ejca.ejca_18_18
)
View on SCiNiTO